Sector News

Boston Scientific acquires EMcision Ltd

March 6, 2018
Life sciences

EMcision Ltd., a privately-held company headquartered in London, UK that develops and commercializes proprietary medical devices, today announced that it and its subsidiaries have been acquired by Boston Scientific, the world’s premier endoscopic devices company.

Founded by internationally renowned surgeon and inventor, Prof. Nagy Habib, EMcision develops innovative devices including the HabibTM 4X, the HabibTM EndoHPB and the HabibTM EUS RFA. Those products have benefited close to 100,000 patients suffering from cancers of the liver, pancreas and bile ducts.

EMcision’s flagship product, the HabibTM EndoHPB, was the world’s first endoscopic device for tumour ablation via ERCP using radiofrequency energy in patients with advanced and inoperable pancreatic cancer and cholangiocarcinoma.

“Recently, two randomised clinical trials showed independently a statistically significant survival advantage for patients treated with the HabibTM EndoHPB,” said Prof. Nagy Habib, EMcision’s Chairman and founder. “This new treatment has empowered endoscopists with a very useful device for management of these unfortunate patients with advanced cancer.”

EMcision devices are sold in 38 countries around the world and used by surgeons and endoscopists in most of the top US cancer centres such as MD Anderson, Memorial Sloan Kettering, Mayo Clinic, Cleveland Clinic, Johns Hopkins, Massachusetts General and Stanford.

“By partnering with Boston Scientific, we will continue delivering on our mission of improving the quality of life of cancer patients on a much larger scale. Boston Scientific has the resources and the know-how to further improve our technology, expand clinical indications and make it available to many more patients,” said Cherif Habib, EMcision’s outgoing CEO.

Boston Scientific, headquartered in Marlborough, Massachusetts, was founded in 1979 and employs over 27,000 people. Their products, across six business divisions, treat over 24 million patients every year.

Source: EMcision

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.